oral glp-1 agonists FDA just approved orforglipron (Foundayo), Eli Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest FDA Adds New Warning

oral glp-1 agonists FDA just approved orforglipron (Foundayo), Eli Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest FDA Adds New Warning

FDA Adds New Warning to GLP-1 Drugs | MedPage Today

Meanwhile, evidence is mounting of the wider therapeutic benefits of GLP-1 drugs, with clinical trials ongoing for metabolic liver disease, cardiovascular diseases, chronic kidney disease, and neurological disorders, among others

The future of pemvidutide (and by extension Altimmune) rests on future trials showing weight reductions that match Wegovy or replicating NASH improvement trends from the Phase 1b (no small feat)